TGA / PMDA / NMPA · Asia-Pacific
injection — TGA / PMDA / NMPA regulatory status
injection regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 954 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 042011 | Phase 3 | George Institute for | 2024-512676-36-00 |
| 071102 | Phase 3 | Baxalta Innovations | 2023-509769-18-00 |
| 105MS306 | Phase 3 | Biogen | 2023-505624-56-00 |
| 111-302 | Phase 3 | BioMarin Pharmaceutical Australia | 2023-508864-31-00 |
| 111-303 | Phase 3 | BioMarin Pharmaceutical Australia | 2024-513129-22-00 |
| 111-308 | Phase 3 | BioMarin Pharmaceutical Australia | 2024-517238-16-00 |
| 14130 | Phase 3 | Regeneron UK | NCT01012973 |
| 165-306 | Phase 3 | BioMarin Pharmaceutical Australia | 2024-510875-39-00 |
| 2-mg Intravitreous Aflibercept Injection | Phase 3 | Regeneron UK | NCT02858076 |
| 20170724 | Phase 3 | Amgen | 2023-506471-10-00 |
| 20170770 | Phase 3 | Amgen | 2023-507149-27-00 |
| 2019/2894 | Phase 3 | George Institute for | 2024-514917-36-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12269856 | Hepcidin analogues and uses thereof | US |
| 2025051711 | TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE | WO |
| 12234300 | Conjugated hepcidin mimetics | US |
| 12233092 | MSC-NTF specific exosomes and use thereof | US |
| 12171864 | Biological self-assembled nanocrystal injection having a lymphatic targeting function and preparation method | US |
| 12070510 | Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid | US |
| 12053619 | Intradermal jet injection electroporation | US |
| 2024094673 | RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH | WO |
| 11807674 | Hepcidin analogues and uses thereof | US |
| 11753443 | Conjugated hepcidin mimetics | US |
| 3230895 | TRAITEMENTS AVEC DES COMPOSES PTH A ACTION PROLONGEE | CA |
| 11541177 | Injection spring for aged prefilled syringe and auto injector | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of injection?
injection currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get injection regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to injection?
This spoke lists 954 published programs associated with injection in our pipeline index.